drugset / Trial / NCT01122511

Safety and Efficacy of Dexamethasone as Adjunctive Therapy to Ranibizumab in Subjects With Choroidal Neovascularization and Age-Related Macular Degeneration

NCT01122511

Phase 2 Terminated 4 enrolled Allergan
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will evaluate the safety and efficacy of dexamethasone (OZURDEX®) as adjunctive therapy to ranibizumab (LUCENTIS®) compared with ranibizumab alone in the treatment of patients with choroidal neovascularization secondary to age-related macular degeneration

Timeline

Start
2010-08
Primary completion
2011-05
Completion
2011-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexamethasone Small molecule 700 ug Intravitreal
Subject Ranibizumab Monoclonal antibody Intravitreal